The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
Sleep and mood support are becoming priorities in functional nutrition as consumers recognise the impact of rest on daily well-being.
Chinese consumers, for instance, have shown the greatest interest in biotics and the role of gut health in supporting mood, stress, and sleep.
According to ADM’s Sleep, Stress & Mood Report, 76% of global consumers agree that sleep quality affects how they feel throughout the day, and 74% believe it influences their overall quality of life.
Diversification across the Asia-Pacific region is gathering pace and fuelling growth for Australia’s supplements sector, according to new data.
China (including Hong Kong) continues to dominate as the largest export destination, accounting for $690million, or 68% of total exports.
However, diversification is gathering pace, with Vietnam strengthening its position as the second-largest market ($86 million, 8%), followed by New Zealand ($49 million, 3%), South Korea ($32 million, 3%), and Thailand ($31 million, 3%).
This year’s supplement successes include creatine, cellular health, and weight loss solutions with plant exosomes, pet nutrition, and shatavari emerging as topics to watch in 2026, according to PharmaLinea’s end-of-year summit.
Creatine, for instance, is “on a great transition journey” from muscle-only to various well-being benefits, Matevž Ambrožič, marketing & PR director at PharmaLinea, pointed out during the session.
This is driven largely by “an immense and growing body of scientific research supporting its benefits for sports performance, muscle, sarcopenia, brain health, skin health, women’s health, and more”.
Women’s health was the most popular dietary supplement category in Australia this year.
Total retail value of women’s health supplements was AUD$375m (US$245m), followed by digestive health (AUD$264m), joint health (AUD$184m), immune system (AUD$158m), and bone health (AUD$136m).
The women’s health category includes products such as women’s multivitamins, which accumulated a total retail value of AUD$97.4m (US$63.6m) or 24.2% of the total multivitamin market, according to an annual industry snapshot report by industry body Complementary Medicines Australia (CMA).
The modernization of traditional remedies, strong uptake of beauty-from-within supplements, and e-commerce as a key channel for health supplement purchase are among the key trends that Boston Consulting Group (BCG) has seen in the region.
The modernization of traditional herbal remedies, for instance, is seen in the case of Jamu – the Indonesian turmeric, ginger, and tamarind drink, which can now be purchased from modern retail channels such as cafes.
Jasryn Ng, principal South East Asia at BCG, highlighted the above during the opening ceremony of Sirio Pharma’s Chonburi factory in Thailand.
XRP Ripple news is buzzing with the ongoing legal tussle between Ripple Labs and the Securities and Exchange Commission (SEC). This battle has not only captured headlines but also significantly impacted XRP’s price. In this article, we’ll explore the current market dynamics around XRPUSD and what the legal outcomes could mean for investors. With XRP’s price currently at $2.03101, reflecting a slight decrease, investors are keenly observing the court proceedings and price predictions.
The Ripple SEC case continues to be a highlight in the crypto world. The case revolves around whether XRP should be considered a security. Ripple Labs argues that it is not, which could vastly impact its market status and regulation. More on the case developments. Court decisions in this case directly influence XRP’s legitimacy and investor confidence. Decisions favoring Ripple could lead to major increases in XRP’s market cap, while setbacks may cause further drops.
Currently, XRP is priced at $2.03101, with a decrease of 0.6%. Despite recent dips, XRP has shown resilience with a year-to-date increase of 5.48%. Over the past year, its value has surged by over 295%, driven by strong investor interest and strategic developments from Ripple Labs. Analysts forecast monthly and quarterly improvements, with predictions at $2.49 and $4.41, respectively. This suggests potential recovery, especially if the legal challenges resolve favorably.
Apart from legal battles, Ripple Labs focuses on expanding its global partnerships and blockchain technology. Recent collaborations and tech enhancements position Ripple favorably in the digital finance landscape. Such strategic moves are crucial for XRP’s stability and growth, offering a buffer against legal headwinds. For investors, keeping an eye on these developments alongside the legal case is essential for informed decision-making.
The investor sentiment around XRP remains mixed but generally optimistic, considering the legal complexities. Social media platforms echo varied sentiments, with discussions focusing on potential bullish outcomes if Ripple wins. According to an analysis of market trends, the technical indicators like RSI and MACD suggest a balanced momentum, while volatility remains moderate. Investors are advised to stay informed about the Ripple SEC case as it unfolds and adjust their strategies accordingly.
The Ripple SEC case remains critical to XRP Ripple news, as the outcome will likely shape the future trajectory of XRP. While current prices show minor declines, the overall increase this year reflects strong investor backing. Potential legal victories could further bolster XRP’s market position, while setbacks might require strategic recalibration. With future forecasts indicating positive trends, investors should remain vigilant and adapt to emerging developments. For up-to-date data and insights, platforms like Meyka offer valuable tools for tracking real-time financial performance and predictions. As the legal case progresses, staying informed and flexible will be crucial for navigating the XRP market landscape.
The case is ongoing, with both sides presenting arguments about whether XRP should be legally defined as a security. Outcomes will significantly affect XRP’s market status and investor sentiment.
The legal challenges have led to price fluctuations. While recent times show declines, XRP has risen significantly over the past year due to investor interest and Ripple’s strategic moves.
Analysts predict monthly and quarterly improvements, with forecasts up to $4.41 quarterly. These predictions depend heavily on legal outcomes and Ripple’s market strategies.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes.
Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
Thursday’s surge fully recovered the top boundaries of two rising trend channels that were briefly lost in the recent pullback. This marks the second successful breakout above both channels since October, distinguishing the current move from the earlier failed attempt and suggesting the market is no longer in an overbought exhaustion state but instead entering a fresh bullish leg across all timeframes.
A weekly close above $4,264 would seal bullish continuation on that timeframe and deliver the third-highest weekly settlement in history if gold finishes above $4,251 tomorrow. The next major objective is the measured move completion at $4,356, where the current second leg up from October exactly matches the price change of the first advance. The standing record high at $4,381 follows immediately, with a 127.2% projection of the second measured move at $4,454, followed by a 161.8% measured move projection.
The entire advance since October has repeatedly respected rising dynamic support. As long as the 20-day average at $4,159 and especially the rising 50-day average at $4,106 remain intact, the multi-timeframe bull trend stays fully on track with room to extend beyond the current record high.
Gold has delivered the highest-probability bullish signal in weeks by clearing $4,264, reclaiming both channel tops, and defending the uptrend line for a third day. A daily and weekly close above $4,264 confirms the new leg and targets $4,356 minimum, then $4,381–$4,454; only loss of the 20-day or 50-day averages would raise legitimate caution for the dominant uptrend.
For a look at all of today’s economic events, check out our economic calendar.
Researchers in India have found that a polyphenol-rich herbal supplement, combining pomegranate and marigold extracts, significantly improved healthy aging parameters in older adults, and in some instances outperformed a mainstay ingredient in the category.
Healthy aging and longevity clearly are hot topics in the supplement and nutraceutical industry. Supplement sales in the healthy aging category are expected to grow at a double-digit pace between now and 2028, according to Nutrition Business Journal analyst Erika Craft.
The study included both objective and subjective measurements, showing participants not only improved according to tests, but noticed a difference in how they felt after taking the supplement for 60 days.
Nicotinamide adenine dinucleotide (NAD+) is a molecule frequently mentioned in healthy aging discussions, as NAD+ levels decrease with age. This coenzyme is highly important at the cellular level, supporting DNA repair and energy metabolism.
NAD precursors are the largest ingredient category in the healthy aging supplement market. NBJ data show this category is likely to double between 2025 and 2028, said Craft.
Two ingredients used most frequently in supplements targeting NAD+ levels are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), both of which are NAD+ precursors. NMN may sound familiar, as it was the subject of recent FDA scrutiny, but now it is reinstated as a dietary supplement.
“The market has been waiting for an NAD+ solution that goes beyond precursors alone,” said Eric Anderson, managing director at NXT USA and CEO of Blue Helix Health, via press release. NXT USA recently launched BluNADBooster, the herbal supplement evaluated in this clinical trial.
“BluNADBooster represents a next-generation approach — one that strengthens the body’s ability to generate and maintain healthy NAD+ levels while addressing the underlying mechanisms that cause NAD+ to decline with age,” he said. “This study confirms what we’ve believed for years: polyphenols matter, and they work in ways synthetic precursors cannot.”
The combination of pomegranate and marigold extracts studied in the clinical trial support healthy aging by boosting NAD+ levels and decreasing age-related depletion of NAD+. The results support the notion that this ingredient also improves cognitive function and physical health.
BluNADBooster is a combination of extracts from pomegranate (Punica granatum) and marigold (Tagetes erecta), standardized to at least 1.5% punicalagins and 4% quercetagetin.
Design: Randomized, double-blind, placebo-controlled trial.
Study size: 140 healthy, older adults with an average age of 60 years.
Dosage: 1,000 mg pomegranate and marigold extract blend (BluNADBooster), 500 mg nicotinamide riboside (NR), 1,000 mg BluNADBooster + 500 mg NR, or placebo.
Outcomes measured: Blood NAD+ levels were measured as well as CD38, an enzyme that “significantly (contributes) to the age-related depletion of NAD+,” according to the study authors. Various inflammatory biomarkers also were measured. Subjects underwent a 6-minute walk test, completed a mini-mental state examination and filled out quality-of-life surveys.
Participants in all treatment groups experienced significantly increased blood NAD+ levels after 60 days compared to baseline.
The increase was greater for BluNADBooster versus nicotinamide riboside, although this was not statistically significant. The combination of both ingredients led to a greater increase in NAD+ than either ingredient alone, but the difference was not statistically significant.
Participants receiving BluNADBooster alone for 60 days had significantly lower CD38 levels than at baseline or those receiving placebo. Subjects who received NR or the combination of actives did not experience significant decreases in CD38, indicating the ability of BluNADBooster not only to boost NAD+ levels but to decrease loss of NAD+ by inhibiting CD38 activity.
All actives significantly decreased tumor necrosis factor alpha and interleukin-6, both of which are proinflammatory cytokines, reducing inflammation in subjects.
Participants walked longer distances in the six-minute walk tests after 60 days of supplementation with all actives, alone or in combination. Similar results emerged with the mini-mental state examinations, indicating all actives improved cognitive performance. BluNADBooster combined with NR produced significantly higher scores than either ingredient alone.
All subjects receiving an active ingredient had improved quality-of-life scores by the end of the trial, indicating they felt a noticeable positive difference beyond what was observed in blood markers and physical tests.
The benefits of nicotinamide riboside and NMN supplementation have been well established in the literature. NAD+ boosters show promise in the treatment Alzheimer’s disease and modulating NAD+ metabolism may benefit immunity and inflammation regulation.
There may also be an opportunity to support NAD+ levels via the gut microbiome and to reduce the severity of age-related diseases.
However, there are few reports of herbal ingredients supporting NAD+ levels. Blue Helix was founded to find “clinically validated, nature-derived innovations” for longevity and metabolic wellness, according to the press release. Blue Helix Health and NXT USA screened 900 herbal extracts to find what they believe to be the optimal solution for boosting NAD+.
“This is comprehensive, multidimensional evidence — science layered on science — to ensure the formulation truly delivers,” Anderson said. “For the first time, we’re seeing a clinically validated botanical strategy that supports multiple hallmarks of aging — including mitochondrial efficiency, inflammation and cognitive resilience — within just 60 days.”
As of December 11, 2025, the dogecoin price today hovers between $0.14 and $0.15, reflecting a week of volatility driven by macroeconomic uncertainty, speculative ETF filings, and uneven liquidity across major exchanges.
Based on market data reviewed for this analysis, Dogecoin maintains a valuation above $21 billion, placing the doge coin within the top tier of crypto assets despite recent weakness. Several widely used indicators—including the 50-day EMA, a tool often referenced to gauge medium-term trend direction—still show downward pressure. Industry sentiment trackers such as various Fear & Greed Index models place broader crypto sentiment in the “extreme fear” category, indicating participants remain cautious after multi-week market declines.
From years of tracking Dogecoin cycles, one consistent observation has been its sensitivity to social sentiment and public commentary. While Dogecoin’s tokenomics—particularly its unlimited supply—continue to raise long-term sustainability questions among analysts, the asset’s deep liquidity and broad community participation often lead to fast-paced responses when trend signals shift.
A long position disclosed by trader @CAGThe3rd on December 10 offered a look into how some short-term traders interpreted an improving structure. The trade was opened at around $0.145661 with a target of $0.1525. According to the trader’s post, the setup was based on bullish EMA crossovers on the 1-hour chart and multiple reactions at the $0.138 support region. EMA crossovers are commonly monitored because they can reflect early changes in momentum when shorter-term averages rise above longer-term ones.
The trader has opened a long Dogecoin position targeting $0.1525, with the setup becoming invalid if the price falls below $0.138. Source: @CAGThe3rd via X
A Coinglass derivatives heatmap from December 10 showed a concentration of short liquidity between $0.15 and $0.16. Coinglass is widely used among derivatives traders because it aggregates futures orderbook data across major exchanges, allowing analysts to identify levels where forced liquidations could occur. Short-liquidation pockets often act as “magnet zones” during upward price movements, especially in assets that exhibit high retail participation.
Dogecoin’s 4% intraday move to $0.148 on the same day aligned with this structure. Intraday chart behavior also formed a higher low near $0.1359, a level that had served as a reaction point several times across December. Based on these patterns, some market watchers noted that buyers were increasingly defending the same structural areas—an early sign of stabilizing sentiment.
It’s important to recognize, however, that individual trader posts represent anecdotal sentiment and not formal research. These insights help illustrate how active participants interpret short-term signals, but they should be balanced with broader technical evidence and risk considerations.
On the 12-hour timeframe—typically used for trend confirmation—Dogecoin is attempting to break out of a falling wedge, a pattern that can indicate weakening bearish momentum. In technical analysis, falling wedges with narrowing price ranges often show that sellers are losing strength. From experience tracking Dogecoin’s multi-year patterns, this structure has historically preceded recoveries only when confirmed by rising volume and improving risk appetite.

The position was closed with a 5.9% gain. Source: DeGRAM on TradingView
The wedge follows a decline from September highs near $0.23, forming through late November and early December. A retest of the upper wedge boundary suggests buyers are evaluating whether momentum is sufficient for continuation, though confirmation remains dependent on stronger volume.
In contrast, a 4-hour chart captured a breakdown below a symmetrical triangle, pushing DOGE from $0.18 into the $0.14 region. Symmetrical triangles in volatile assets like the cryptocurrency dogecoin can break in either direction, but when they break downward with rising volume, they often lead to continuation moves. Based on the formation’s height, some traders estimated a potential move toward the $0.11 region if bearish momentum resumes.
This downward move occurred after Federal Reserve Chair Jerome Powell’s December 10 remarks indicating a cautious stance on rate cuts. Historically, comments suggesting tighter financial conditions tend to pressure risk assets, including digital currencies.
The contrast between the 12-hour bullish wedge and the 4-hour bearish triangle highlights a key reality for readers: Shorter timeframes reflect intraday sentiment, while longer timeframes are more reliable for trend confirmation.
Dogecoin currently trades within a broader support band between $0.08 and $0.12, a range that has historically preceded accumulation phases. Analysts who monitor midpoint structures emphasize that a meaningful shift in momentum would require a decisive break above the descending trendline and a sustained close above $0.15. This level serves as a psychological and structural boundary, with multiple liquidity pockets stacked below it.

Dogecoin is retesting its 12-hour falling wedge breakout, with a successful retest potentially setting up a 50–55% short-term rally. Source: @GlobeOfcrypto1 via X
If DOGE manages a confirmed breakout, technical models—based on measured-move calculations commonly used in trend analysis—point toward:
Initial resistance around $0.22
A secondary zone near $0.29
A continuation path that could revisit the broader $0.30 region
These projections are not guarantees. They assume strengthened volume, improving sentiment, and continued defense of higher lows. Failure to maintain support at $0.135–0.138 would weaken the bullish setup and raise the risk of a return toward the lower accumulation range near $0.12.
Across short- and mid-term ranges, market structure has gradually shifted in favor of buyers. Dogecoin has rejected deeper declines several times, particularly at the $0.135 pivot, where lower wicks have indicated absorbing demand. Price compression into tighter ranges often signals an impending expansion phase, though direction remains dependent on external catalysts.
The $0.150–$0.155 zone remains pivotal. A break above this region would likely invalidate several bearish short-term patterns and open the door toward the $0.18 liquidity cluster. Beyond $0.181, historical regression levels show resistance near $0.210 and $0.270.

Dogecoin is consolidating between $0.08 and $0.12, and a breakout above the descending trendline—especially beyond $0.15—would likely confirm a return to bullish momentum. Source: MMBTtrader on TradingView
Long-term Dogecoin predictions remain divided. While questions such as “Will Dogecoin reach $1?” continue to circulate in retail discussions, analysts emphasize that sustainable valuation increases require structural improvements—such as growing merchant adoption, improved utility, and reduced speculative dependence. Still, Dogecoin’s strong brand recognition and active community help maintain its relevance across market cycles.
Forecasts for 2025 vary widely due to Dogecoin’s inherent volatility. More conservative models expect the dogecoin price prediction for 2025 to fall between $0.17 and $0.39, depending on broader crypto-market performance, ETF adoption, and macroeconomic conditions. These projections are typically based on historical regression curves and cycle comparisons.

Dogecoin was trading at around $0.14, down 6.16% in the last 24 hours. Source: Brave New Coin
More aggressive forecasts cite the potential impact of spot Dogecoin ETFs, though early trading volumes have been mixed. Claims that Dogecoin could reach $10 remain speculative and would require unprecedented market-cap expansion.
In the near term, most technical models suggest continued consolidation between $0.14 and $0.146 unless DOGE can break above $0.15, which would strengthen the case for a move toward $0.1525 and higher. As always, these outlooks depend on evolving data, market liquidity, and the broader risk environment.
In the wake of the latest Federal Reserve decision to lower its benchmark rate by 25 basis points, bringing the federal funds rate range to 3.50%–3.75%, Gold (XAU/USD) extended its upside momentum. Spot gold climbed decisively above $4,200, with early Asian session trade showing levels near $4,235 — a meaningful move from the prior floor near the $4,200 psychological zone. This price expansion followed the dovish undertones embedded in the Fed’s communication, even though policymakers stopped short of signaling a clear pace of further easing. Lower interest rates decrease the opportunity cost of holding a non-yielding asset like gold, underpinning bullion’s advance into new territory.
The broader macroeconomic backdrop continues to bolster XAU/USD. The U.S. dollar index weakened to multi-week lows following the rate cut, easing downward pressure on gold and further validating bullion’s appeal as an alternative store of value. Real yields have compressed in response to both the rate move and nascent expectations for slower monetary tightening into 2026, enhancing gold’s relative attractiveness for investors seeking protection against currency depreciation and inflation threats.
Technical price action reflects a subtle shift from relentless rallying to measured consolidation. Despite the yield-friendly policy backdrop, traders observed a pause in upside conviction as XAU/USD hovered near the $4,210–$4,235 corridor. Intraday dips toward the $4,190–$4,200 range found buying support, indicating demand remains intact even amid short-term profit-taking. On shorter timeframes, gold dipped below $4,200 but reclaimed levels around $4,206, signaling that bidders are actively defending this zone, which might be crucial for sustaining a broader uptrend.
Medium-term technical setups underscore gold’s resilience. The 20-day exponential moving average (EMA) near $4,163 is acting as a dynamic support level, above which the uptrend remains structurally intact. The next major support tier, anchored by the 50-day EMA at approximately $4,051, serves as a deeper cushion should short-term consolidation evolve into a deeper pullback. Momentum indicators — including the daily RSI near 61 — reveal moderated but constructive strength, not exhaustion. These signals show that gold’s pullbacks are normal pauses within a larger bullish trajectory rather than shifts in trend direction.
Gold’s ascent has not occurred in macro isolation. Heightened geopolitical tensions — including the U.S. seizure of a sanctioned Venezuelan tanker and ongoing uncertainty around Russia-Ukraine peace negotiations — have continually bolstered safe-haven demand. These geopolitical risks amplify the appetite for non-yielding precious metals, helping gold maintain firm footing even when short-term market narratives grapple with mixed data.
While traders initially responded favorably to the 0.25% rate cut, doubts about the timeline for subsequent rate adjustments have clouded near-term sentiment. Fed Chair Jerome Powell’s cautious commentary — emphasizing a wait-and-see approach — left open the possibility of either pausing or adjusting the pace of policy ease in 2026. This ambiguity has given gold markets cause for caution around the $4,250 resistance level. Breaking and holding above this threshold would reinforce the path toward new record highs, while failure could invite deeper reversion toward key supports.
Looking at futures quotes on the CME for February gold contracts, the immediate upside targets remain entrenched above former highs. The contract’s near-term resistance resides at the previous overnight high near $4,277.70, followed by the psychological plateau around $4,300. Traders and technical models also point toward the all-time contract high at $4,433 as a marquee target should momentum reignite. On the flip side, downside risk objectives are defined by supports at $4,231.20 and deeper near $4,197.80, which mark key intraday lows from recent sessions.
Domestic price trends in India — one of the world’s largest gold consumers — reflect international spot pressures and currency and import tax effects. On December 11, 2025, 24K gold in major Indian cities such as Mumbai and Chennai traded near ₹130,630 per 10 grams, up approximately ₹1,080 (0.83%) from the previous close. Similarly, 22K gold hovered around ₹119,744 per 10 grams (0.83% gain), while 18K recorded ₹97,973 per 10 grams (0.83% gain). These increases underline the linkage between international bullion prices and domestic markets, where import costs, currency fluctuations, and local demand dynamics converge to shape retail pricing.
The upward trajectory in bullion extends beyond gold. Silver futures — exemplified by March contracts — surged with gains upward of $1.446 to $62.47, hitting fresh record highs amid the same macro support structures that buoy gold. This broad metals performance – driven by real-rate compression, safe-haven flows, and industrial demand – reinforces a growing narrative that both gold and silver are benefitting from dovish monetary policy mixed with persistent geopolitical risks.
A notable shift in the post-FOMC landscape was the Fed’s announcement of a $40 billion monthly Treasury bill purchase program, aimed at alleviating pressures in short-term funding markets. While this program hasn’t yet reverberated emphatically through gold prices, the added liquidity factor introduces another dimension to markets already digesting rate cuts and weakening yields. The interplay between quantitative measures and traditional monetary easing continues to shape expectations for real rates, a key driver for gold’s longer-term valuation.
Despite recent rallies, markets are eyeing consolidation as gold transitions from rapid rally to price digestion. Pullbacks toward the $4,190–$4,200 range reflect profit taking as traders recalibrate ahead of key macro announcements and potential geopolitical developments. Importantly, such retracements occur within a broader structural uptrend, supported by consistent EMAs and macro drivers.
The trajectory for XAU/USD now hinges on how markets interpret future Fed direction and the U.S. dollar’s behavior. A continuation of dollar weakness, accompanied by clear expectations of additional rate cuts, would likely fortify gold’s bid and accelerate momentum toward record territory. Conversely, if rate expectations stabilize or the dollar rebounds, gold may experience range-bound trading with support anchoring near critical EMAs.
Based on the interplay of macro data, price structure, and geopolitical inputs, gold’s rally shows structural strength but faces short-term resistance and consolidation. Key support levels near $4,190–$4,200 and medium-term EMAs offer potential entry points for disciplined buyers. A clean break above $4,250 would reinforce further upside, while failures to hold recent ranges may invite deeper tests. Given the persistence of safe-haven demand, real-rate support, and technical structure, a Hold bias with selective accumulation on dips — particularly under $4,150 — aligns with current market behavior.
usatoday.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on usatoday.com
Cardano Price Prediction discussions are changing as market cycles reward projects with clear execution paths. Large layer one networks still matter, though many ADA holders are now weighing progress versus potential. Payment focused crypto, PayFi infrastructure, and real world utility are taking more space in investor thinking.
Within this shift, Remittix is entering conversations early as a payments driven network built around daily use. That growing interest sits beside the broader Cardano Price Prediction debate, where traders compare network pace, developer delivery, and capital rotation as 2026 approaches.
Cardano Price Prediction metrics remain sensitive to short term structure. ADA trades at $0.4616, up 8.19% over the last 24 hours, with a market capitalization of $16.64 billion. Trading volume reached $1.58 billion, jumping 146.79%, signaling active positioning rather than passive holding.
A widely shared technical outlook posted by Justcryptopays outlines two paths, which you can review in this Cardano price action breakdown. As long as micro support near $0.447 holds, price momentum may stretch toward $0.54.
A breakdown near that zone could shift pressure toward $0.345, leaving ADA in a wait and react phase tied closely to the Cardano Price Prediction outlook.
Market behavior around these levels shows hesitation rather than conviction. Short term traders remain active, though longer term holders appear more cautious as ADA approaches decision points.
This split behavior explains why Cardano Price Prediction discussions continue to focus on structure instead of momentum, with risk management taking priority over upside assumptions.
This technical pause also reflects broader market rotation. As capital searches for clearer execution stories, ADA price action is judged against projects delivering visible progress. Until Cardano commits to one direction, the Cardano Price Prediction remains anchored to support defense and volume follow through rather than trend continuation signals.
Remittix is entering these discussions through visible product delivery rather than speculation. The Remittix Wallet is now live on the Apple App Store, giving users a functioning crypto wallet to store, send, and manage assets. This marks the first phase of its PayFi ecosystem, with crypto to fiat payments scheduled for integration next.
The project is also expanding beta wallet testing to more iOS community members, increasing real user feedback ahead of the next release.
Confidence around Remittix has grown for structural reasons. The project has raised over $28.5 million through private funding, sold more than 693 million tokens, and trades at $0.119 per RTX. These signals place it directly inside conversations around crypto solving real world problems.
Remittix recently achieved full team verification by CertiK and currently ranks first among projects tracked before listing, reinforcing transparency and trust. The project has also confirmed future centralized exchange listings on BitMart and LBank, expanding expected liquidity access when trading begins.
Alongside this, a live referral system now offers 15% USDT rewards, paid daily, supporting organic community growth rather than short term hype.

Why Remittix Is Gaining Attention:
These factors explain why Remittix is increasingly mentioned alongside Cardano Price Prediction debates, especially by ADA holders weighing payment utility as a defining theme for 2026.
Discover the future of PayFi with Remittix by checking out their project here:
Website: https://remittix.io/
Socials: https://linktr.ee/remittix
$250,000 Giveaway: https://gleam.io/competitions/nz84L-250000-remittix-giveaway
Cardano Price Prediction depends on whether ADA holds support near $0.447. Volume growth shows interest, though price direction remains undecided.
Some ADA holders are seeking exposure to PayFi networks with live products. Remittix offers a working wallet and payment focused roadmap.
Yes. The Remittix Wallet is live on the Apple App Store, with crypto to fiat functionality planned as a future update.
The Remittix token is priced at $0.119 and funding has come entirely from private funding sources.
Could PayFi dominate crypto narratives in 2026?
Many traders believe payment focused crypto will grow as real world adoption increases, placing projects like Remittix alongside ongoing Cardano Price Prediction debates.
You’ve probably seen the hepatitis B vaccine in the news lately.
If you’re wondering what the buzz is about, let’s start with the basics.
Hepatitis B is a liver infection caused by the hepatitis B virus (HBV). The infection can be short-term or last for life, and it can cause severe complications such as liver failure, liver cancer and even death.
“Hepatitis B is a dangerous infection — it can be life-threatening for a person of any age who contracts it,” said Deborah L. Wexler, M.D., founder and executive director emerita of the Immunization Action Coalition.
The hepatitis B virus is highly contagious, so it spreads very easily through body fluids. Even sharing a toothbrush can transmit HBV. And the virus can also live on surfaces for days.
About half of people with hepatitis B don’t have symptoms, which means they can pass on the virus without even knowing they have it.
The great news is that hepatitis B is preventable, thanks to the vaccine. Since 1991, the recommendation has been to give the first of three doses of the hepatitis B vaccine to all newborns at birth. After the recommendation was implemented, hepatitis B infections in children decreased by 99%.
This is where the latest news comes in: Earlier this month, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to withdraw the recommendation to vaccinate every newborn for hepatitis B at birth (called the “universal birth dose”) and now recommends the birth dose only for newborns whose mothers test positive for the virus. For other newborns, ACIP now recommends that they should get the first dose of the vaccine “no earlier than two months of age.”
Wexler, who has spent much of her career helping implement the birth dose in the U.S., said rolling back the universal birth dose recommendation is dangerous for a few reasons.
For one, many pregnant people aren’t tested for hepatitis B, which puts their newborns at risk during childbirth.
When newborns and children up to 5 are infected, they often become lifelong carriers of the virus and are more likely to have serious health problems.
The best way to prevent hepatitis B infection is by getting vaccinated.
Here are 4 things you need to know about the hepatitis B vaccine.
Most people have life-long immunity after getting the hepatitis B vaccine. But you have to get all the doses for full protection.
The number of shots and the amount of time you have to wait between doses varies depending on the vaccine.
Decades of research have shown that the vaccine is safe and effective in protecting against hepatitis B and that side effects, if any, are mild.
Hepatitis B is spread through contact with infected body fluids (saliva, vaginal fluids, semen, blood).
Most people are exposed to the virus through:
But you can also contract hepatitis B off of infected surfaces. The vaccine protects against all types of exposure to the virus.
Waiting two months to give the hepatitis B vaccine opens up a two-month window for babies to get the virus when their immune systems are young and vulnerable. In addition, not all pregnant people are tested for active or chronic hepatitis B. In fact, in the U.S., an estimated 500,000 pregnant women are not tested each year, so their status is unknown at the time of delivery.
Wexler said the vaccine is a matter of public safety and helps you and your loved ones — and really everyone — live free from chronic liver disease.
“[Without the universal birth dose], a lot of those babies will fall through the cracks. If there’s no hepatitis B result on the chart and they’re not vaccinated, then those children are at severe risk for hepatitis B from their mothers. So the universal birth dose is a safety net — and safety nets are what public health is about. We have the opportunity to eliminate hepatitis B from the United States — and from all over the world — by utilizing this vaccine,” Wexler said.
From Your Site Articles
Related Articles Around the Web
At 15:15 GMT, January Natural Gas Futures are trading $4.326, down $0.269 or -5.85%.
Thursday’s EIA report is expected to show a sharply above-average storage withdrawal, reflecting last week’s colder-than-normal temperatures across the Midwest and Northeast. Forecast ranges are wide, from -167 Bcf to -174 Bcf, versus the five-year average draw of -89 Bcf.
While a draw of this magnitude would normally offer support, sentiment remains bearish due to the forecasted warmup. A strong print may provide only limited relief if traders believe next week’s milder pattern will suppress demand.
According to NatGasWeather, national demand will remain high through the weekend as frigid systems move through the Midwest and East. Highs in the 10s–30s and lows below freezing are expected to dominate through Sunday. However, next week’s forecast flips dramatically, with above-normal temperatures expected to spread across most of the Lower 48, sharply reducing heating demand into Christmas.
This warm bias has taken center stage for traders, undermining the impact of near-term cold and limiting upside momentum.
The break below $4.495, previously serving as the 50-day moving average, triggered heavy liquidation as algorithmic and technical traders exited long positions. A cascade of selling followed as the $4.390 level failed, leaving the October 29 low at $4.052 as the next downside marker. Without supportive weather or sustained demand, the market appears vulnerable to further retracement.